A Double-Blind, Randomized, Vehicle-Control, Multicenter Study to Evaluate the Efficacy and Safety of NAFT900 in Children With Tinea Capitis Aged 6 to < 13 Years

Trial Profile

A Double-Blind, Randomized, Vehicle-Control, Multicenter Study to Evaluate the Efficacy and Safety of NAFT900 in Children With Tinea Capitis Aged 6 to < 13 Years

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Naftifine (Primary)
  • Indications Tinea capitis
  • Focus Therapeutic Use
  • Sponsors Merz Pharmaceuticals
  • Most Recent Events

    • 08 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 21 Jul 2016 Planned End Date changed from 1 Sep 2016 to 1 Mar 2017.
    • 21 Jul 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top